Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (595)	1/4/2001 6:58:53 AM
From: smh	Respond to of 805

Thursday January 4, 6:00 am Eastern Time StemCells, Inc. Names Martin McGlynn New President and Chief Executive Officer Former Pharmadigm CEO to Lead Executive Management Team Effective January 15, 2001 SUNNYVALE, Calif.--(BUSINESS WIRE)--Jan. 4, 2001--StemCells, Inc. (Nasdaq: STEM - news) announced today that effective January 15th, Martin McGlynn will become President and CEO of the Company. McGlynn brings several decades of international experience in the Life Sciences industry to his position. Prior to joining StemCells, Inc., he was President and CEO of Pharmadigm, Inc., a privately held company in Salt Lake City, Utah, which is engaged in research and development in the fields of inflammation and genetic immunization. During his time at Pharmadigm, McGlynn took the company through four rounds of financing, raising in excess of $50 million in private and venture capital. Mr. McGlynn's prior experience includes President of Anaquest Inc., the Pharmaceutical Products Division of BOC Health Care and Vice President, Abbott International and President and General Manager of Abbott Canada Ltd. ``We are extremely pleased that Martin is joining us,'' said John Schwartz, Chairman of the Board of Directors of StemCells, Inc. ``We believe his experience and leadership skills make him ideal for StemCells at this point. We are also grateful to George Dunbar for the leadership he has provided the Company as it turned its focus to its core business of stem cell technology and for his continued involvement with the Company during our search for a new CEO.'' Mr. Dunbar has been Acting President and CEO of StemCells since February 2000. Mr. McGlynn is a native of Dublin, Ireland and began his Life Sciences career at Becton Dickinson Ireland, Ltd. He holds a Bachelor of Commerce from University College Dublin, and diplomas in Industrial Engineering and Production Planning from the Irish Institute of Industrial Engineering and the University of Birmingham, respectively. StemCells Inc. is a company engaged in the use of stem cell technology in the treatment of diseases characterized by damage to, or degeneration of, the central nervous system (CNS), liver, pancreas and other tissue.